In the current study, we examined the types and frequency of KIT mutations in mast cell tumors from 191 dogs. Sequencing of reverse transcription-PCR products revealed alterations in 50 (26.2%) of the dogs. Most mutations were in exon 11 (n = 32), and of these, most were internal tandem duplications (n = 25) between residues 571 and 590. Within exon 11, there were two hotspots for mutations at codons 555-559 and 571-590. In addition, nine dogs had mutations in exon 8 and eight had mutations in exon 9. We selected the two most common mutants and two representative exon 11 mutants for further analysis. When expressed in Ba/F3 cells, they were constitutively tyrosine phosphorylated and induced growth factor -independent cell proliferation. AG1296, a tyrosine kinase inhibitor, dose dependently inhibited both the tyrosine phosphorylation of these mutants and their induction of growth factor -independent proliferation. This study shows that activating mutations in not only exon 11 but also exons 8 and 9 are common in canine mast cell tumors. These results also show that Ba/F3 cells can be used for the direct characterization of canine KIT mutants, eliminating the need to make equivalent mutations in the mouse or human genes.
Introduction
The KIT gene encodes a transmembrane type III tyrosine kinase that is the receptor for stem cell factor (SCF; ref. 1). The protein includes an extracellular domain composed of five immunoglobulin-like domains (encoded by exons 1-9), a transmembrane domain (exon 10), and an intracellular domain (exons [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The intracellular domain is further divided into a negative regulatory juxtamembrane domain (exons 11 and 12) and a cytoplasmic tyrosine kinase domain that is split by an insert into ATP-binding (exon 13) and phosphotransferase lobes (exon 17). As in many other receptor tyrosine kinases, ligand binding induces receptor dimerization, which activates the tyrosine kinase, resulting in autophosphorylation and the phosphorylation of exogenous substrates. These phosphorylations then lead to downstream signal transduction.
Gain-of-function mutations of KIT (i.e., mutations that cause constitutive activation of the KIT tyrosine kinase) are associated with gastrointestinal stromal tumors, acute myelogenous leukemia, sinonasal T-cell lymphomas, and seminomas/dysgerminomas in humans (1) . Such activating mutations, especially the well-known D 816 V substitution, which lies in exon 17, have also been implicated in mastocytosis, a relatively rare multidimensional disease associated with mast cell infiltration into cutaneous and sometimes noncutaneous tissues, including bone marrow, spleen, and liver (2) .
Previous studies have also identified KIT mutations in canine mast cell tumors. Mast cell neoplasms are one of the most common tumors in dogs, accounting for f20% of all tumors (3) . Mast cell tumors tend to occur in middle-aged to elderly dogs (mean age of f9 years), with a predominance in Boxers, Terriers, and Labrador Retrievers (4) . The clinical course of the disease varies from benign to highly malignant. Most tumors are benign, develop slowly, and persist for years without increasing in size or metastasizing. However, a large number are highly aggressive and present a significant threat to canine health.
Known KIT mutations associated with canine mast cell tumors include internal tandem duplications (ITD) and small insertions and deletions in the intracellular juxtamembrane region (exons 11 and 12; refs. 5-8) . In support of the idea that activating KIT mutations play a causative role in canine mast cell tumors, a phase I trial published in 2003 showed that SU11654 (Sugen), an inhibitor of several receptor tyrosine kinases including KIT, causes significant shrinkage or stabilization of mast cell tumors (9) . A more recent study by Kobie et al. (10) also found that the tyrosine kinase inhibitor STI571 (Glivec; Novartis) induces the regression of xenografted canine mast cell tumors in severe combined immunodeficient mice. Finally, Gleixner et al. (11) very recently reported that a variety of tyrosine kinase inhibitors that can inhibit KIT suppress the proliferation of canine mastocytoma cell lines.
In the current study, we examined the types and frequency of KIT mutations in canine mast cell tumors. We also examined the effects of the identified mutations on KIT function to gain insight into the pathogenesis of the different mutations and to clarify the role of KIT in mast cell and other diseases. This was the largest study of this type to date, involving 191 dogs. Although a majority of the mutations were found in exon 11, we show for the first time that mutations in exons 8 and 9, which encode the fifth immunoglobulin-like domain, are common in canine mast cell tumors. We tested the four most common of these mutations, and all activated the KIT tyrosine kinase. Finally, as part of this study, we developed and validated a system that allows the direct expression and analysis of canine KIT mutants, eliminating the need to make and analyze equivalent mutations in the mouse or human KIT genes.
Results

Alterations in KIT in Canine Mast Cell Tumors
Previous studies in a variety of species, including dog, have identified mutations in exons 8, 9, 11, and 17 of KIT (1). We therefore examined the sequences of exons 8 to 13 and 17 to 19 of KIT in canine mast cell tumors. A total of 202 dogs were enrolled, and sequences were obtained from 191. The majority of the dogs were mixed breeds, and the remainder included Labrador, Golden Retriever, Boxer, Rhodesian Ridgeback, Weimaraner, and other breeds (data not shown). Biopsies were taken from an enlarged mass (previous tumor, cutaneous metastasis, or internal organ) previously confirmed to be a mast cell tumor. We first cloned and sequenced exons 8 to 13 and 17 to 19 using reverse transcription-PCR. All genetic alterations were confirmed by sequencing of an independent reverse transcription-PCR. Genetic alterations were found in 50 (26.2%) of the 191 dogs (Table 1 ; Fig. 1 ). Of the 50 dogs with mutations, most (n = 32) had mutations in exon 11. Mutations were also frequently found in exons 8 (n = 9) and 9 (n = 8), and a single dog had a mutation in exon 17.
Within exon 11, rare in-frame mutations and deletions (Del 555-557 InsV, Del 556-557 , K 557 InsF, K 557 N InsP, and K 557 R Del 558-559 ) were identified in the proximal (5 ¶) region. Most of the alterations (n = 25) were ITDs located in the distal part (3 ¶) of exon 11 between residues 571 and 590 (ITD [571] [572] [573] [574] [575] [576] [577] [578] [579] [580] [581] [582] [583] [584] [585] [586] [587] [588] [589] [590] ). The mutations in exon 8 included a frequent (n = 8) ITD (12-bp duplication), resulting in the insertion of the amino acid sequence QILT at residue 421 (ITD [417] [418] [419] [420] [421] ) and a single case of a Q 430 R substitution. Mutations in exon 9 included five cases of a S 479 I substitution and three of a N 508 I substitution. The single mutation found in exon 17 was a deletion of residues 826 to 828 coupled with an insertion of a DT sequence (Del 826-828 InsDT). In addition to these mutations, we found that all 191 dogs had three nucleotides that differed from the reported sequence for canine KIT in Genbank ( Table 2) . Two of these changes, c.1818C>T p. and c.2007A>T p., were conservative, and the third, c.1325G>A p., resulted in an amino acid change at codon 442 (G 442 D). Because our study included a large number of dogs and a variety of species, we suspect that these differences are errors in the published sequence or that there are polymorphisms at these sites. We also found evidence for common (>20% of the dogs) conservative polymorphisms at three additional codons (c.1275G>A p., c.1731C>T p., and c.2355G>A p.).
Expression of Canine KIT in Mouse Ba/F3 Cells
Activating mutations in KIT have previously been identified in canine mast cell tumors; however, demonstration that the mutations are activating has required the generation and analysis of equivalent mutants in human or mouse KIT (6, 12) . To avoid this time-consuming step and to directly analyze the effect of the mutations identified in this study, we searched for a system in which cDNAs encoding canine wild-type (WT) and mutant forms of KIT could be functionally expressed. For this purpose, we focused on mouse Ba/F3 cells, an interleukin-3 (IL-3)-dependent hematopoietic cell line that has been previously used to examine the function of human KIT mutants (13) . This cell line is becoming an increasingly important tool for characterizing protein tyrosine kinases and for the discovery of tyrosine kinase inhibitors (14) . (15) . These mutants were expressed in Ba/F3 cells, and after selection of transfected cells with G418, cell surface expression of KIT was verified by fluorescence-activated cell sorting (FACS) using ACK45, a monoclonal antibody to murine KIT that cross-reacts with canine KIT ( Fig. 2 ; ref. 16 ). We also confirmed expression of KIT on C2 canine mastocytoma cells, which have been previously shown to express a mutant of KIT (6) . In contrast, untransfected Ba/F3 cells ( Fig. 2 , dotted lines) did not express KIT.
Tyrosine Phosphorylation of Canine KIT in Ba/F3 Cells
Binding of SCF by KIT causes receptor dimerization, which then activates the tyrosine kinase domain, leading to receptor autophosphorylation. Oncogenic mutations in KIT act by enhancing the sensitivity to SCF or by constitutively activating the tyrosine kinase domain of KIT (1) . Therefore, to examine the activity of the four selected mutants, we immunoprecipitated KIT from Ba/F3 cells and analyzed its tyrosine phosphorylation by Western blotting. Western blotting of the immunoprecipitates with a murine KIT antibody confirmed that the transfected Ba/F3 cells contain KIT protein, whereas KIT was not detected in untransfected Ba/F3 cells (Fig. 3A , bottom).
Western blotting with an antibody to phosphotyrosine confirmed that WT KIT was tyrosine phosphorylated only in the presence of SCF (Fig. 3A, top) , whereas all four of the mutant KIT proteins were maximally phosphorylated in the absence of SCF. Similarly, in C2 cells, KIT was constitutively phosphorylated in the absence of SCF. Finally, these results show that mouse SCF activates canine KIT.
Effect of the Canine KIT Mutants on the Proliferation of Ba/F3 Cells
Ba/F3 cells are an IL-3 -dependent cell line, and previous studies have shown that expressing activated mutants of KIT in these cells induces growth factor -independent proliferation (12, 13) . Therefore, we next examined the growth of the transfected Ba/F3 cells in the presence and absence of SCF and IL-3 ( Fig. 3B) . In all cases, IL-3 induced maximal cell proliferation. As expected, Ba/F3 cells transfected with WT canine KIT did not proliferate in the absence of added growth factors but rapidly proliferated in the presence of SCF. In contrast, all four of the tested mutants induced growth factorindependent proliferation that was not enhanced by SCF. Of the tested KIT mutants, Del 555-557 InsV caused the most rapid cell proliferation. C2 cells also underwent rapid growth factorindependent proliferation that was not enhanced by SCF.
The Tyrosine Kinase Inhibitor AG1296 Inhibits Growth Factor -Independent Proliferation of Ba/F3 Cells Expressing Canine KIT Mutants
Our results revealed that canine KIT mutants common in mast cell tumors can be functionally expressed in murine Ba/F3 cells. The results further suggest that these mutations cause growth factor -independent proliferation by constitutively acti- Table 1 ). vating the KIT tyrosine kinase. To confirm the causative role of KIT tyrosine kinase activation in growth factor -independent cell proliferation and to validate the Ba/F3 system for the functional characterization of canine KIT, we next examined the effect of AG1296, an inhibitor of several receptor tyrosine kinases including KIT (12), on KIT tyrosine phosphorylation and KIT-dependent proliferation in Ba/F3 cells. Immunoprecipitation-Western blotting experiments showed that AG1296 dose dependently inhibits SCF-stimulated tyrosine phosphorylation of WT KIT expressed in Ba/F3 cells. AG1296 also dose dependently inhibited the ligand-independent phosphorylation of all four tested canine KIT mutants in Ba/F3 cells, although compared with the other mutants, the S 479 I mutant was relatively insensitive (Fig. 4A ). AG1296 also dose dependently inhibited the SCF-simulated proliferation of Ba/F3 cells expressing WT canine KIT as well as the growth factor -independent proliferation of cells expressing the four canine KIT mutants. In all cases, 50% inhibition was reached at approximately 0.3 to 3 Amol/L of AG1296 (Fig. 4B) . IL-3 -stimulated proliferation of Ba/F3 cells was much less insensitive to AG1296, with 50% inhibition reached at f30 Amol/L.
Of the four mutants, S 479 I mutant was the least sensitive to the inhibitor. To determine whether this insensitivity was shared by other exon 9 mutants, we also examined the N 508 I mutant. We found that this mutation constitutively activated KIT tyrosine phosphorylation, but, unlike S 479 I, it was sensitive to AG1296 (Supplementary Fig. S1 ).
Finally, mutations in exon 17, such as D 816 V, are known to activate KIT but to be insensitive to most tyrosine kinase inhibitors (17) . Similarly, we found that the Del 826-828 InsDT mutation activated KIT but was insensitive to inhibition by AG1296 (Supplementary Fig. S1 ).
Discussion
In the current study, we examined the types and frequency of KIT mutations in canine mast cell tumors from 191 dogs. We also assessed the effects of four of the most common mutations on KIT function to gain insight into the pathogenesis of canine mast cell tumors and other mast cell diseases. This was the largest and most comprehensive analysis of the role of KIT mutations in canine mast cell tumors to date.
Mutations in KIT were found in just over one quarter (26.2%) of the dogs. A majority of the mutations (64%) were in exon 11, but we also found a significant number (34%) in exons 8 and 9. Only a single dog had a mutation in exon 17 (Del [826] [827] [828] InsDT). Interestingly, like the human D 816 V mutant, this canine mutant seems to be insensitive to tyrosine kinase inhibitors. Mutations in exon 11 are associated with higher grades of canine mast cell tumors (18) and an increased incidence of recurrent disease and death due to mast cell tumors (19) . Mutations in this exon are also found in a majority of human gastrointestinal stromal tumors and are associated with a poor prognosis (20) . Of the mutations in exon 11, most (25 of 32) were ITDs. This high frequency of ITDs in exon 11 agrees with previous findings in canine mast cell tumors (5, 6, 8, 21) , although the overall distribution of mutations contrasts with that in human mastocytosis, where mutations in exon 17 (i.e., codon 816) are found in the majority of cases and mutations in exon 11 are rare (1). 8 Further analysis of the specific sites of the mutations within exon 11 reveals two hotspots, one between residues 555 and 559 and a second between residues 571 and 590 (Fig. 1) . Previous studies of canine mast cell tumors revealed the clustering of mutations in these regions (6, 18) . One of the two hotspots in exon 11 is around a key tryptophan at residue 556 (corresponding to residue 557 in human KIT), which is inserted into a pocket in the protein kinase domain when the receptor is inactive (22) . The other hotspot consists of a variety of ITDs between residues 571 and 590. Interestingly, the hotspots surround but do not include two tyrosines (residues 567 and 569, corresponding to residues 568 and 570 in human) that are principal sites of autophosphorylation following receptor dimerization, supporting the idea that the phosphorylation of these two residues and/or sequences surrounding these two residues are essential for kinase activation (22) .
Exon 11 encodes the intracellular juxtamembrane region, which, in the inactive state, maintains the two lobes of the kinase domain in a closed conformation (1). Thus, mutations in exon 11, including Del 555-557 InsV and ITD 572-586 , probably activate KIT tyrosine phosphorylation by disrupting the structure of the juxtamembrane region, releasing it from the kinase domain.
Although less common than mutations in exon 11, a substantial portion (17 of 50) of the mutations were in exons 8 (Q 430 R and ITD [417] [418] [419] [420] [421] ) and 9 (S 479 I and N 508 I). We also recently found that mutations in exons 8 and 9 are very common in childhood mastocytosis. 8 The ITD at residue 417-421 includes a residue (419 in human) that is also mutated in human patients with mastocytosis and myeloproliferative disorder-acute myeloid leukemia (23) (24) (25) . Our recent study of childhood mastocytosis also identified a hotspot for mutations consisting of codons 417 to 419. 8 In addition, the N 508 I substitution (equivalent to residue 505 in human), which also activated KIT, is near a residue (509 in human) that is mutated from lysine to isoleucine in familial mastocytosis (26) . It also lies within a hotspot for mutations (codons 501-509) in human gastrointestinal stromal tumor (1) and childhood mastocytosis. 8 These residues lie COOH terminus to and within the fifth immunoglobulin-like domain. A recent crystallographic study showed that the fifth immunoglobulinlike domain forms homotypic contacts in the ligand-dependent dimer of KIT, and it was suggested that oncogenic mutations in this region act by enhancing the binding affinity of these interactions, leading to activation of the intracellular kinase domain (27) .
Our characterization of canine KIT mutants was greatly simplified by the use of mouse Ba/F3 cells; previous studies of canine KIT mutants have required the generation of equivalent mutations in the human or mouse cDNA (6, 11) . These studies in Ba/F3 cells showed not only that all of the tested mutants activate KIT tyrosine phosphorylation but also that they induced growth factor -independent cell proliferation.
In these studies, we used C2 canine mastocytoma cells as a positive control for KIT expression and detection. These cells express KIT with a 48-bp tandem duplication in the juxtamembrane domain (6) . We show here that, like the tested mutant proteins, KIT in the C2 cells is constitutively tyrosine phosphorylated in the absence of SCF. Consistent with this, Gleixner et al. (11) recently reported that inhibitors of KIT can block the proliferation of C2 cells in culture.
We further showed that AG1296, an inhibitor of KIT and other receptor tyrosine kinases, inhibits not only the ligandindependent tyrosine phosphorylation of the four tested mutants but also their ability to cause growth factor -independent proliferation. This agrees with a previous report by Ueda et al. (12) that AG1296 inhibits the constitutive tyrosine phosphorylation and induction of growth factor -independent proliferation by murine KIT with an activating mutation in the juxtamembrane domain. Although AG1296 potently inhibited the induction of Ba/F3 cell proliferation by the canine KIT mutants, it was a weak inhibitor of IL-3 -stimulated cell proliferation. Unexpectedly, tyrosine phosphorylation and induction of cell proliferation by the S 479 I mutant was relatively insensitive to AG1296. This insensitivity does not seem to be a general feature of exon 9 mutations because the N 508 I mutant was sensitive to AG1296. We found the same results using the tyrosine kinase inhibitor PP2 (data not shown), supporting the idea that the inhibition of both cell proliferation and KIT tyrosine phosphorylation is due to the inhibition of tyrosine kinase activity. The fact that both AG1296 and PP2 inhibited mutant KIT-induced cell proliferation at lower concentrations than IL-3 -induced cell proliferation suggests that the effects of these agents are KIT specific and not due to disruption of pathways generally involved in cell proliferation or survival.
Overall, the rank order of inhibition for the four tested mutants was the same in the Western blots and the cell proliferation. However, there was a difference in the doseresponse curves between the cell proliferation and tyrosine phosphorylation experiments: in all cases, AG1296 was roughly 10-fold more potent at inhibiting cell proliferation than KIT tyrosine phosphorylation. Similar results were found with PP2, another tyrosine kinase inhibitor (data not shown). Such differences are often observed with inhibitors of protein kinases (e.g., see refs. 28, 29) and may have multiple causes. First, nonlinearities in the Western blots may have caused the IC 50 for tyrosine phosphorylation to appear at a higher concentration. Second, the downstream pathways leading to cell proliferation may have been more sensitive to perturbations in the kinase activity than autophosphorylation. Third, preexisting phosphotyrosine on KIT (i.e., occurring before the addition of inhibitor) may be lost slowly and cause the autophosphorylation to appear to be less sensitive to an inhibitor than cell proliferation. This would not be apparent with WT KIT, which is only phosphorylated in the presence of SCF. Fourth, the inhibitors could affect multiple enzymes or pathways. Indeed, AG1296 and PP2 are known to inhibit several tyrosine kinases (30) (31) (32) , and it is possible that the phosphorylation of downstream effectors or the activity of tyrosine kinases downstream of KIT is more sensitive to AG1296 and PP2 than KIT itself. Because both AG1296 and PP2 were potent inhibitors of mutant KIT-induced cell proliferation in all cases, it seems that, at a minimum, tyrosine kinase activity is necessary for their transforming activity. Furthermore, the fact that the rank order of potency in the Western blots is the same as in the cell proliferation assay argues that KIT tyrosine phosphorylation and the induction of cell proliferation are directly linked. Overall, the differences in the dose-response curves are most likely due to the limitations of the assays, and these results suggest that constitutive activation of the tyrosine kinase domain drives the induction of cell proliferation by canine KIT mutants.
In sum, our results suggest that activating mutations in KIT are common and play a causative role in canine mast cell tumors. This agrees with a previous study showing that the tyrosine kinase inhibitor SU11654 (Sugen) causes significant shrinkage or stabilization of canine mast cell tumors (9) . Another study by Kobie et al. (10) recently reported that the tyrosine kinase inhibitor STI571 (Glivec) induces the regression of xenografted canine mast cell tumors in severe combined immunodeficient mice. We also show here for the first time that mutations in exons 8 and 9 are common, whereas mutations in exon 17 are rare in canine mast cell tumors. This contrasts with the reported distribution of KIT mutations in both adult and childhood forms of mastocytosis (1). 8 The results presented here should help clarify how transforming mutations in KIT lead to disease. In particular, they point out the importance of the fifth immunoglobulin-like domain in receptor activation. This information should aid in the development of treatments for mast cell tumors as well as human KIT-mediated diseases. Finally, we showed that Ba/F3 cells can be used to directly express and characterize canine KIT, avoiding the need to generate equivalent mutations in mouse or human cDNAs.
Materials and Methods
Animals
The analysis of KIT mutations in canine mast cell tumors was done as part of a phase III study on the treatment of canine mast cell tumors with the tyrosine kinase inhibitor AB1010. Female and male dogs, regardless of breed, were recruited with owner consent from 25 Cutaneous biopsies (f5 mm) were taken from an enlarged mass (previous tumor, cutaneous metastasis, or internal organ) previously confirmed to be a mast cell tumor. Biopsies were submerged immediately in RNAlater (Qiagen) to a volume of f1 mL and stored at room temperature. Total RNA was isolated using an RNeasy Mini kit (Qiagen) as recommended by the manufacturer. The extracted RNA (200 ng) was reverse transcribed in a 25-AL reaction containing random hexamers (Stratagene) and the StrataScript First-Strand Synthesis System (Stratagene). A 2.5-AL sample of the resulting cDNA was then amplified by PCR using the primers covering exons 8 to 13 and 17 to 19 (Table 3) . PCR was carried out for 40 cycles at 94jC for 30 s, 57jC for 30 s, and 72jC for 45 s. Amplimers were purified with the GeneClean III kit (Qbiogene) and directly sequenced with the BigDye Terminator v.1.1 kit (Applied Biosystems) and sequencing primers (Table 3) on an ABI Prism 3130 sequencer (Applied Biosystems). Observed mutations were systematically checked in a new reverse transcription reaction. This method was able to detect the mutated allele when present in 5% to 10% of the cells.
Cloning and Expression of Full-Length WT and Mutant Canine KIT
RNA from normal and tumor biopsies was extracted and reverse transcribed as described above (see ''Cloning and Sequencing of Exons 8 to 13 and 17 to 19 of KIT from Canine Mast Cell Tumors'') except using oligo(dT) to prime cDNA and ThermoScript reverse transcriptase (Invitrogen). Each full-length cDNA was then amplified by PCR using canine KIT-specific primers containing attB sites at their 5 ¶ ends (Table 3) , which allows the rapid and efficient cloning of PCR products into the attP-containing donor vector (pDON R201) using the Gateway system (Invitrogen). Each PCR productcontaining vector was then sequenced to verify both the KIT sequence integrity and the presence of the introduced KIT mutations. Next, a LR recombination reaction was done between donor vectors and the LXSN GW attR-containing destination vector. Ba/F3 cells (5 Â 10 6 in 300 AL RPMI 10) were mixed with 100 AL of PBS containing 15 Ag KIT-encoding LXSN GW plasmid and subjected to electroporation using a Gene Pulser (Bio-Rad Laboratories) at 250 V and 960 AF for 30 ms. The transfected cells were selected in RPMI 10 containing 1 mg/mL G418 for 14 d.
Cells and Growth Conditions
Untransfected Ba/F3 cells or Ba/F3 cells expressing WT canine KIT were grown at 37jC in RPMI 10 (RPMI 1640 with L-glutamine, with 100 units/mL penicillin, 100 Ag/mL streptomycin, and 10% heat-inactivated FCS) supplemented with 0.1% conditioned medium from X63-IL-3 cells (34) . Ba/F3 cells expressing mutants of KIT were grown in RPMI 10 without added cytokines. The C2 canine mastocytoma cell line, which expresses KIT with a 48-bp tandem duplication in the juxtamembrane domain (6), was provided by Douglas H. Thamm (Department of Clinical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI) and grown at 37jC in RPMI 10.
Fluorescence-Activated Cell Sorting
Surface expression of KIT was verified by FACS using 10 Ag/mL of ACK45 anti-KIT monoclonal antibody (BD Biosciences). Events were collected using a FACScan (Becton Dickinson) and analyzed using FlowJo software (Treestar).
Analysis of KIT Tyrosine Phosphorylation
Ba/F3 cells (5 Â 10 6 ) expressing WT or mutant KIT were serum starved for 3 h in RPMI. In some experiments, cells were treated for 1.5 h with RPMI containing 0 to 25 Amol/L of AG1296 (Calbiochem). Cells were then treated for 5 min at 37jC with or without 250 ng/mL recombinant murine SCF, which was purified from the conditioned medium of SCFproducing CHO cells (gift of S. Lyman, Immunex). The cells were then placed on ice and washed with ice-cold PBS and lysed in 500 AL of ice-cold HNTG buffer [50 mmol/L HEPES (pH 7), 50 mmol/L NaF, 1 mmol/L EGTA, 150 mmol/L NaCl, 1% Triton X-100, 10% glycerol, 1.5 mmol/L MgCl 2 ] containing a mixture of protease inhibitors (Roche Applied Science) and 100 Amol/L Na 3 VO 4 . Cell lysates were mixed overnight at 4jC with 2 Ag of purified rat anti-mouse CD117 (KIT) monoclonal antibody ACK45 (BD Biosciences) and 50 AL of a 20% slurry of protein G-Sepharose (Amersham Biosciences Europe GmbH) in PBS. The beads were washed in cold HTNG and resuspended in 20 AL of 2Â electrophoresis sample buffer. The immunoprecipitated proteins were then separated by SDS-PAGE on an 8% acrylamide gel. Proteins were electrophoretically transferred onto a polyvinylidene difluoride membrane (Millipore SAS). Membranes were blocked in TBS containing 0.05% Tween 20 and 5% bovine serum albumin for 30 to 45 min at room temperature. Western blotting for KIT was done using 1:1,000 dilution of a polyclonal rabbit anti-KIT antibody (Cell Signaling Technology), followed by 1:10,000 horseradish peroxidase -conjugated anti-rabbit antibody, and, for phosphotyrosine, using 1:1,000 anti-phosphotyrosine antibody 4G10 (Cell Signaling Technology), followed by 1:20,000 horseradish peroxidase -conjugated anti-mouse antibody. Immunoreactive bands were detected using enhanced chemiluminescent reagents (Pierce).
Assay of Cell Proliferation
A total of 10 4 cells per well were seeded into 96-well plates in 100 AL of RPMI 1640 with 10% fetal bovine serum with or without 0.1% conditioned medium from X63-IL-3 cells or 250 ng/mL murine SCF at 37jC. The murine SCF, which activates dog KIT, was purified from the conditioned medium of SCF-producing CHO cells (gift of S. Lyman). In some experiments, the medium was supplemented with 0 to 30 Amol/L of the tyrosine kinase inhibitor AG1296 (Calbiochem). Cells were grown for 48 h at 37jC and then incubated with 10 AL/well of WST-1 reagent (Roche Applied Science) for 3 h at 37jC. The amount of formazan dye formed was measured using a scanning multiwell spectrophotometer (MultiSkan MS, Thermo-LabSystems). The absorbance of the samples was measured at 450 nm. A background control without cells was used as a blank for the spectrophotometer. Experiments were done in triplicate, and the means and SDs were calculated.
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